DC homeostasis in hematopoietic stem cell transplantation

Cytotherapy

Volumn 9, Issue 6, 2007, Pages 521-531

  Collin, Matthew P ^a   Bogunovic, M ^a   Merad, M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Dendritic cell; Graft versus host disease; Homeostasis; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; CALCINEURIN INHIBITOR; CLODRONIC ACID; DENDRITIC CELL VACCINE; FINGOLIMOD; FLUDARABINE; GLUCOCORTICOID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LIPOSOME; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NK 026680; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTATION; ARTICLE; CELL INTERACTION; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CELLULAR IMMUNITY; CLINICAL FEATURE; CORD BLOOD STEM CELL TRANSPLANTATION; DENDRITIC CELL; DONOR LYMPHOCYTE INFUSION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HISTOCOMPATIBILITY; HOMEOSTASIS; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN TARGETING; T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; GRAFT VS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOMEOSTASIS; HUMANS;

EID: 34648846220     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240701507314     Document Type: Article

References (130)

1. Ford, CE, Hamerton, JL, Barnes, DW and Loutit, JF. (1956) Cytological identification of radiation-chimaeras. Nature, 177, pp. 452-454.
2. Baron, F., Storb, R. and Little, MT. (2003) Hematopoietic cell transplantation: Five decades of progress. Arch Med Res, 34, pp. 528-544.
3. Hambach, L. and Goulmy, E. (2005) Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol, 17, pp. 202-210.
4. Burroughs, L. and Storb, R. (2005) Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease. Curr Opin Hematol, 12, pp. 45-54.
5. Barrett, AJ and Savani, BN. (2006) Stem cell transplantation with reduced-intensity conditioning regimens: A review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia, 10, pp. 1661-1672.
6. Storb, R., Deeg, HJ and Whitehead, J. (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med, 314, pp. 729-735.
7. Gratwohl, A., Brand, R. and Apperley, J. (2002) Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood, 100, pp. 3877-3886.
8. Kanda, Y., Izutsu, K. and Hirai, H. (2004) Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. Leukemia, 18, pp. 1013-1019.
9. Diaconescu, R., Flowers, CR and Storer, B. (2004) Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood, 104, pp. 1550-1558.
10. Bryson, JS, Jennings, CD and Caywood, BE (1997) Enhanced graft-versus-host disease in older recipient mice following allogeneic bone marrow transplantation. Bone Marrow Transplant, 19, pp. 721-728.
11. Weiden, PL, Flournoy, N. and Thomas, ED (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med, 300, pp. 1068-1073.
12. Weiden, PL, Sullivan, KM and Flournoy, N. (1981) Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med, 304, pp. 1529-1533.
13. Ho, VT and Soiffer, RJ. (2001) The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood, 98, pp. 3192-3204.
14. Kolb, HJ, Schmid, C., Barrett, AJ and Schendel, DJ. (2004) Graft-versus-leukemia reactions in allogeneic chimeras. Blood, 103, pp. 767-776.
15. Haan, JM den, Sherman, NE and Blokland, E. (1995) Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science, 268, pp. 1476-1480.
16. Dickinson, AM, Wang, XN and Sviland, L. (2002) In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med, 8, pp. 410-414.
17. Bleakley, M. and Riddell, SR. (2004) Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer, 4, p. 371.
18. Mapara, MY and Sykes, M. (2004) Tolerance and cancer: Mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol, 22, pp. 1136-1151.
19. Kolb, HJ and Holler, E. (1997) Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol, 9, pp. 139-145.
20. Schroeder, ML. (2002) Transfusion-associated graft-versus-host disease. Br J Haematol, 117, pp. 275-287.
21. Johnson, BD and Truitt, RL. (1995) Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood, 85, pp. 3302-3312.
22. Mackinnon, S., Papadopoulos, EB and Carabasi, MH (1995) Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood, 86, pp. 1261-1268.
23. Shlomchik, WD. (2003) Antigen presentation in graft-vs.-host disease. Exp Hematol, 31, pp. 1187-1197.
24. Korngold, R. and Sprent, J. (1980) Selection of cytotoxic T-cell precursors specific for minor histocompatibility determinants. I. Negative selection across H-2 barriers induced with disrupted cells but not with glutaraldehyde-treated cells: Evidence for antigen processing. J Exp Med, 151, pp. 314-327.
25. Korngold, R. and Sprent, J. (1982) Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers. J Exp Med, 155, pp. 872-883.
26. Sprent, J., Schaefer, M. and Korngold, R. (1986) Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences. J Exp Med, 163, pp. 998-1011.
27. Gao, EK, Kosaka, H., Surh, CD and Sprent, J. (1991) T cell contact with Ia antigens on nonhemopoietic cells in vivo can lead to immunity rather than tolerance. J Exp Med, 174, pp. 435-446.
28. + T cells by semiprofessional antigen-presenting cells in vivo. J Exp Med, 176, pp. 1291-1302.
29. Shlomchik, WD, Couzens, MS and Tang, CB (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science, 285, pp. 412-415.
30. + T cell-mediated acute graft-versus-host disease. J Clin Invest, 109, pp. 1335-1344.
31. Teshima, T., Ordemann, R. and Reddy, P. (2002) Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med, 8, pp. 575-581.
32. Matte, CC, Liu, J. and Cormier, J. (2004) Donor APCs are required for maximal GVHD but not for GVL. Nat Med, 10, pp. 987-992.
33. Blaser, BW, Schwind, NR and Karol, S. (2006) Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity. Blood, 108, pp. 2463-2469.
34. + T cell-mediated graft-versus-host disease model. J Clin Invest, 112, pp. 1880-1886.
35. Anderson, BE, McNiff, JM and Jain, D. (2005) Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: Requirements depend on target organ. Blood, 105, pp. 2227-2234.
36. Mapara, MY, Kim, YM and Wang, SP (2002) Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: A critical role for host antigen-presenting cells. Blood, 100, pp. 1903-1909.
37. + antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood, 110, pp. 9-17.
38. Reddy, P., Maeda, Y. and Liu, C. (2005) A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med, 11, pp. 1244-1249.
39. Shortman, K. and Liu, YJ. (2002) Mouse and human dendritic cell subtypes. Nat Rev Immunol, 2002, pp. 151-161.
40. Ito, T., Liu, YJ and Kadowaki, N. (2005) Functional diversity and plasticity of human dendritic cell subsets. Int J Hematol, 81, pp. 188-196.
41. Hart, DN. (1997) Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood, 90, pp. 3245-3287.
42. Banchereau, J. and Steinman, RM. (1998) Dendritic cells and the control of immunity. Nature, 392, pp. 245-252.
43. Duffner, UA, Maeda, Y. and Cooke, KR (2004) Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol, 172, pp. 7393-7398.
44. Xia, G., Truitt, RL and Johnson, BD. (2006) Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant, 12, pp. 397-407.
45. + T cells to elicit hepatic graft-versus-host disease. J Immunol, 169, pp. 7111-7118.
46. Rowe, V., Banovic, T. and MacDonald, KP (2006) Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood, 108, pp. 2485-2492.
47. Siegal, FP, Kadowaki, N. and Shodell, M. (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science, 284, pp. 1835-1837.
48. Colonna, M., Trinchieri, G. and Liu, YJ. (2004) Plasmacytoid dendritic cells in immunity. Nat Immunol, 5, pp. 1219-1226.
49. Liu, YJ. (2005) IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol, 23, pp. 275-306.
50. Brook, MO, Wood, KJ and Jones, ND. (2006) The impact of memory T cells on rejection and the induction of tolerance. Transplantation, 82, pp. 1-9.
51. Austyn, JM, Kupiec-Weglinski, JW, Hankins, DF and Morris, PJ. (1988) Migration patterns of dendritic cells in the mouse. Homing to T cell-dependent areas of spleen, and binding within marginal zone. J Exp Med, 167, pp. 646-651.
52. Randolph, GJ, Inaba, K. and Robbiani, DF (1999) Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity, 11, pp. 753-761.
53. Kissenpfennig, A., Henri, S. and Dubois, B. (2005) Dynamics and function of Langerhans cells in vivo: Dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity, 22, pp. 643-654.
54. Pugh, CW, MacPherson, GG and Steer, HW. (1983) Characterization of nonlymphoid cells derived from rat peripheral lymph. J Exp Med, 157, pp. 1758-1779.
55. Hemmi, H., Yoshino, M. and Yamazaki, H. (2001) Skin antigens in the steady state are trafficked to regional lymph nodes by transforming growth factor-beta1-dependent cells. Int Immunol, 13, pp. 695-704.
56. Huang, FP, Platt, N. and Wykes, M. (2000) A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med, 191, pp. 435-444.
57. Scheinecker, C., McHugh, R., Shevach, EM and Germain, RN. (2002) Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med, 196, pp. 1079-1090.
58. Belz, GT, Behrens, GM and Smith, CM (2002) The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med, 196, pp. 1099-1104.
59. Steinman, RM, Hawiger, D. and Nussenzweig, MC. (2003) Tolerogenic dendritic cells. Annu Rev Immunol, 21, pp. 685-711.
60. Caux, C., Ait-Yahia, S. and Chemin, K. (2000) Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol, 22, pp. 345-369.
61. Ruedl, C., Koebel, P. and Bachmann, M. (2000) Anatomical origin of dendritic cells determines their life span in peripheral lymph nodes. J Immunol, 165, pp. 4910-4916.
62. Kamath, AT, Henri, S. and Battye, F. (2002) Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood, 100, pp. 1734-1741.
63. Kamath, AT, Pooley, J. and O'Keeffe, MA (2000) The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J Immunol, 165, pp. 6762-6770.
64. Merad, M., Manz, MG and Karsunky, H. (2002) Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol, 3, pp. 1135-1141.
65. Merad, M., Hoffmann, P. and Ranheim, E. (2004) Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med, 10, pp. 510-517.
66. Katz, SI, Tamaki, K. and Sachs, DH. (1979) Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature, 282, pp. 324-326.
67. Kabashima, K., Banks, TA and Ansel, KM (2005) Intrinsic lymphotoxin-beta receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity, 22, pp. 439-450.
68. Diao, J., Winter, E. and Cantin, C. (2006) In situ replication of immediate dendritic cell (DC) precursors contributes to conventional DC homeostasis in lymphoid tissue. J Immunol, 176, pp. 7196-7206.
69. Bogunovic, M., Ginhoux, F. and Wagers, A. (2006) Identification of a radio-resistant and cycling dermal dendritic cell population in mice and men. J Exp Med, 203, pp. 2627-2638.
70. Liu, K., Waskow, C. and Liu, X. (2007) Origin of dendritic cells in peripheral lymphoid organs of mice. Nat Immunol, 8, pp. 578-583.
71. Goto, Y., Hogg, JC and Suwa, T. (2003) A novel method to quantify the turnover and release of monocytes from the bone marrow using the thymidine analog 5′-bromo-2′-deoxyuridine. Am J Physiol Cell Physiol, 285, p. C253.
72. Collin, MP, Hart, DN and Jackson, GH (2006) The fate of human Langerhans cells in hematopoietic stem cell transplantation. J Exp Med, 203, pp. 27-33.
73. Kanitakis, J., Petruzzo, P. and Dubernard, JM. (2004) Turnover of epidermal Langerhans' cells. N Engl J Med, 351, pp. 2661-2662.
74. Geissmann, F., Jung, S. and Littman, DR. (2003) Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity, 19, pp. 71-82.
75. Edwards, EW and Tacke, F. (2004) Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes. J Exp Med, 200, pp. 1231-1241.
76. Ginhoux, F., Tacke, F. and Angeli, V. (2006) Langerhans cells arise from monocytes in vivo. Nat Immunol, 7, pp. 265-273.
77. Naik, SH, Metcalf, D. and van Nieuwenhuijze, A. (2006) Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat Immunol, 7, pp. 663-671.
78. Bruno, L., Seidl, T. and Lanzavecchia, A. (2001) Mouse pre-immunocytes as non-proliferating multipotent precursors of macrophages, interferon-producing cells, CD8alpha(+) and CD8alpha(-) dendritic cells. Eur J Immunol, 31, pp. 3403-3412.
79. + dendritic cells. Blood, 100, pp. 569-577.
80. Hoyo, GM del, Martin, P. and Vargas, HH (2002) Characterization of a common precursor population for dendritic cells. Nature, 415, pp. 1043-1047.
81. Diao, J., Winter, E. and Chen, W. (2004) Characterization of distinct conventional and plasmacytoid dendritic cell-committed precursors in murine bone marrow. J Immunol, 173, pp. 1826-1833.
82. + splenic dendritic cells. Blood, 103, pp. 2668-2676.
83. Yrlid, U., Jenkins, CD and MacPherson, GG. (2006) Relationships between distinct blood monocyte subsets and migrating intestinal lymph dendritic cells in vivo under steady-state conditions. J Immunol, 176, pp. 4155-4162.
84. Fogg, DK, Sibon, C. and Miled, C. (2006) A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science, 311, pp. 83-87.
85. Teshima, T., Ordemann, R. and Reddy, P. (2002) Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med, 6, pp. 575-581.
86. Kaplan, G., Nusrat, A. and Witmer, MD (1987) Distribution and turnover of Langerhans cells during delayed immune responses in human skin. J Exp Med, 165, pp. 763-776.
87. Bennett, CL, van Rijn, E. and Jung, S. (2005) Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol, 169, pp. 569-576.
88. Kaplan, DH, Jenison, MC and Saeland, S. (2005) Epidermal Langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity, 23, pp. 611-620.
89. Barrett, AJ, Mavroudis, D. and Tisdale, J. (1998) T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant, 21, pp. 543-551.
90. Peggs, KS, Thomson, K. and Hart, DP (2004) Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood, 103, pp. 1548-1556.
91. Auffermann-Gretzinger, S., Lossos, IS and Vayntrub, TA (2002) Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood, 99, pp. 1442-1448.
92. Chan, GW, Gorgun, G., Miller, KB and Foss, FM. (2003) Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biol Blood Marrow Transplant, 9, pp. 170-176.
93. Clark, FJ, Freeman, L. and Dzionek, A. (2003) Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease. Transplantation, 75, pp. 221-225.
94. Pihusch, M., Boeck, S. and Hamann, M. (2005) Peripheral dendritic cell chimerism in allogeneic hematopoietic stem cell recipients. Transplantation, 80, pp. 843-849.
95. Boeck, S., Hamann, M. and Pihusch, V. (2006) Kinetics of dendritic cell chimerism and T cell chimerism in allogeneic hematopoietic stem cell recipients. Bone Marrow Transplant, 37, pp. 57-64.
96. Nachbaur, D., Kircher, B. and Eisendle, K. (2003) Phenotype, function and chimaerism of monocyte-derived blood dendritic cells after allogeneic haematopoietic stem cell transplantation. Br J Haematol, 123, pp. 119-126.
97. Porta, MD, Rigolin, GM and Alessandrino, EP (2004) Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. Eur J Haematol, 72, pp. 18-25.
98. Fagnoni, FF, Oliviero, B. and Giorgiani, G. (2004) Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation. Blood, 104, pp. 281-289.
99. Perreault, C., Pelletier, M. and Belanger, R. (1985) Persistence of host Langerhans cells following allogeneic bone marrow transplantation: possible relationship with acute graft-versus-host disease. Br J Haematol, 60, pp. 253-260.
100. Auffermann-Gretzinger, S., Eger, L. and Bornhauser, M. (2006) Fast appearance of donor dendritic cells in human skin: Dynamics of skin and blood dendritic cells after allogeneic hematopoietic cell transplantation. Transplantation, 81, pp. 866-873.
101. Baron, F., Baker, JE and Storb, R. (2004) Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood, 104, pp. 2254-2262.
102. Mielcarek, M., Martin, PJ and Leisenring, W. (2003) Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood, 102, pp. 756-762.
103. Hill, GR, Cooke, KR and Brinson, YS (1999) Pretransplant chemotherapy reduces inflammatory cytokine production and acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation, 67, pp. 1478-1480.
104. Hill, GR, Crawford, JM and Cooke, KR (1997) Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood, 90, pp. 3204-3213.
105. Lee, YR, Yang, IH and Lee, YH (2005) Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood, 105, pp. 3951-3955.
106. Mehling, A., Grabbe, S. and Voskort, M. (2000) Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol, 165, pp. 2374-2381.
107. Piemonti, L., Monti, P. and Allavena, P. (1999) Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol, 162, pp. 6473-6481.
108. Klangsinsirikul, P., Carter, GI and Byrne, JL (2002) Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood, 99, pp. 2586-2591.
109. Buggins, AG, Mufti, GJ and Salisbury, J. (2002) Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood, 100, pp. 1715-1720.
110. Mapara, MY, Kim, YM, Marx, J. and Sykes, M. (2003) Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: Extinction of graft-versus-leukemia effects after conversion to full donor chimerism. Transplantation, 76, pp. 297-305.
111. + regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci USA, 103, pp. 2758-2763.
112. Morison, WL. (1989) Effects of ultraviolet radiation on the immune system in humans. Photochem Photobiol, 50, pp. 515-524.
113. Ullrich, SE. (1995) The role of epidermal cytokines in the generation of cutaneous immune reactions and ultraviolet radiation-induced immune suppression. Photochem Photobiol, 62, pp. 389-401.
114. Barr, RM, Walker, SL and Tsang, W. (1999) Suppressed alloantigen presentation, increased TNF-alpha, IL-1, IL-1Ra, IL-10, and modulation of TNF-R in UV-irradiated human skin. J Invest Dermatol, 112, pp. 692-698.
115. + Langerhans-like dendritic antigen-presenting cells are concomitantly depleted. J Invest Dermatol, 105, pp. 782-788.
116. Yuksel, M., Baron, E. and Camouse, M. (2006) Peritransplant use of ultraviolet-B irradiation (UV-B) therapy is detrimental to allogeneic stem cell transplantation outcome. Biol Blood Marrow Transplant, 12, pp. 665-671.
117. Hoetzenecker, W., Meingassner, JG and Ecker, R. (2004) Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol, 122, pp. 673-684.
118. Fujii, S., Shimizu, K. and Fujimoto, K. (2001) Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells. Leuk Lymphoma, 42, pp. 357-369.
119. Sato, K., Yamashita, N. and Yamashita, N. (2003) Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity, 18, pp. 367-379.
120. Hock, BD, Fearnley, DB and Boyce, A. (1999) Human dendritic cells express a 95 kDa activation/differentiation antigen defined by CMRF-56. Tissue Antigens, 53, pp. 320-334.
121. Hock, BD, Starling, GC, Daniel, PB and Hart, DN. (1994) Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. Immunology, 83, pp. 573-581.
122. Collin, MP, Munster, D. and Clark, G. (2005) In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: implications for the control of graft-versus-host disease. Transplantation, 79, pp. 722-725.
123. Blazar, BR, Korngold, R. and Vallera, DA. (1997) Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev, 157, pp. 79-109.
124. Lan, YY, De Creus, A. and Colvin, BL (2005) The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am J Transplant, 5, pp. 2649-2659.
125. Kim, YM, Sachs, T. and Asavaroengchai, W. (2003) Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest, 111, pp. 659-669.
126. Maraskovsky, E., Pulendran, B. and Brasel, K. (1997) Dramatic numerical increase of functionally mature dendritic cells in FLT3 ligand-treated mice. Adv Exp Med Biol, 417, pp. 33-40.
127. Laouar, Y., Welte, T., Fu, XY and Flavell, RA. (2003) STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity, 19, pp. 903-912.
128. McKenna, HJ, Stocking, KL and Miller, RE (2000) Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood, 95, pp. 3489-3497.
129. Whartenby, KA, Calabresi, PA and McCadden, E. (2005) Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci USA, 102, pp. 16741-16746.
130. Saiga, K., Toyoda, E. and Tokunaka, K. (2006) NK026680, a novel compound suppressive of dendritic cell function, ameliorates mortality in acute lethal graft-versus-host reaction in mice. Bone Marrow Transplant, 37, pp. 317-323.